[Correspondence] Edaravone for treatment of early-stage ALS

The Edaravone (MCI-186) ALS 19 Study Group1 reported on the safety and efficacy of edaravone in a phase 3 study of patients with early-stage amyotrophic lateral sclerosis. The primary endpoint was change in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores from baseline to 24 weeks after randomisation. Before randomisation, patients entered a 12-week observation period, and those patients with a decrease in ALSFRS-R score of 1 –4 points were randomly assigned to receive edaravone or placebo.

Source: Lancet Neurology - September 13, 2017 Category: Neurology Authors: Jes ús S Mora Tags: Correspondence Source Type: research